fedratinib hydrochloride · Bristol-Myers · NDA 212327
Inrebic
Earliest generic entry, as listed
24 Sep 2039
Blocked by patent: US 11400092. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11400092 | use U-3409 | 24 Sep 2039 |
| US 10391094 | product, use U-2607 | 4 Jun 2032 |
| US 7528143 | substance, product | 16 Nov 2031 |
| US 8138199 | use U-2607 | 30 Jun 2028 |
| US 7825246 | substance | 16 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212327 · 001 · RLD | capsule, oral | EQ 100MG BASE | 24 Sep 2039 |
Expired or delisted (1)
- ODE-259 · 16 Aug 2026